Clinical Trials Browser

Phase 2 × Interventional × Prostatic Neoplasms × Clear all

NCT03866382 2026-04-16

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Phase 2 Recruiting

Urachal adenocarcinoma, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Penile Neoplasms, Prostatic Neoplasms, Urethral Neoplasms, Urogenital Neoplasms

NCT05616650 2026-04-16

Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor

Phase 2 Recruiting

Prostatic Neoplasms

NCT06347705 2026-04-16

A Study of 2141-V11 in Combination With Standard Treatments in People With Prostate Cancer

Phase 2 Recruiting

Prostatic Neoplasms

NCT03821792 2026-04-15

Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT06161506 2026-04-15

Surface Electrical Stimulation for Urinary Incontinence in Men Treated for Prostate Cancer

Phase 2 Recruiting

Prostatic Hyperplasia, Prostatic Neoplasms, Urinary Incontinence, Urinary Incontinence, Stress, Urinary Incontinence, Urge

NCT07111507 2026-04-15

A Study of Tarlatamab for People With Prostate Cancer

Phase 2 Recruiting

Prostatic Neoplasms

NCT07237269 2026-04-15

Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer

Phase 2 Recruiting

Prostatic Neoplasms

NCT01902680 2026-04-14

CURIEFOCALE

Phase 2 Completed

Prostatic Neoplasms

NCT05828082 2026-04-14

Testing the Effect of M1774 on Hard-to-Treat Refractory SPOP-mutant Prostate Cancer

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT05960578 2026-04-14

Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT02225704 2026-04-13

Radium-223 in Combination With Enzalutamide

Phase 2 Completed

Prostatic Neoplasms

NCT02465060 2026-04-13

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Phase 2 Active not recruiting

6,452 enrolled 2 FDA

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT02772588 2026-04-13

AASUR in High Risk Prostate Cancer

Phase 2 Completed

64 enrolled 7 charts

Prostatic Neoplasms

NCT02893917 2026-04-13

Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer

Phase 2 Active not recruiting

90 enrolled 19 charts

Prostatic Neoplasms

NCT02960022 2026-04-13

A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Phase 2 Recruiting

Prostatic Neoplasms

NCT03869762 2026-04-13

DICE

Phase 2 Terminated

Neoplasm Metastasis, Prostatic Neoplasms

NCT04337580 2026-04-13

FASN

Phase 2 Recruiting

Neoplasms, Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant

NCT04550494 2026-04-13

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

Phase 2 Recruiting

BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms

NCT04842890 2026-04-13

Phase II Study of Pencil Beam Scanning Proton Stereotactic Body Radiation Therapy for Prostate Cancer

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT05691465 2026-04-13

Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells

Phase 2 Recruiting

Prostatic Neoplasms

NCT05849298 2026-04-13

PSMACare

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT06594926 2026-04-13

WOMBAT

Phase 2 Recruiting

Prostatic Neoplasms

NCT06610825 2026-04-13

CaRPET

Phase 2 Recruiting

Prostatic Neoplasms

NCT07220720 2026-04-13

POSLUMA® (18F-rhPSMA-7.3) PET-CT for PIRADS 2/3 Lesions

Phase 2 Recruiting

Prostatic Neoplasms

NCT00859781 2026-04-08

177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer

Phase 2 Active not recruiting

55 enrolled 11 charts

Prostatic Neoplasms

NCT05053152 2026-04-08

Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT07047118 2026-04-08

A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Phase 2 Active not recruiting

Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant

NCT06632977 2026-04-07

PREDICT

Phase 2 Recruiting

Prostatic Neoplasms

NCT07515651 2026-04-07

MIDAS-SBRT

Phase 2 Not yet recruiting

Adenocarcinoma, Prostatic Neoplasms

NCT07516210 2026-04-07

ART-Hypo

Phase 2 Not yet recruiting

GastrointestinalGenitourinaryGynecologic

Uterine Cervical Neoplasms, Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Endometrial Neoplasms

NCT03173924 2026-04-06

18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer

Phase 2 Active not recruiting

Disease, Prostatic Neoplasms

NCT03976843 2026-04-06

Prostate Specific Membrane Antigen (PMSA)-Based PET Imaging of High Risk Prostate Cancer

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT04709276 2026-04-06

CHAMP

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT05361798 2026-04-06

A Phase II Study Evaluating T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combination With the Immunocytokine PDS01ADC in Localized High and Intermediate Risk Prostate Cancer Treated With Androgen Deprivation Therapy

Phase 2 Recruiting

Prostatic Neoplasms

NCT07512076 2026-04-06

A Dose Optimization Study of Enzalutamide in Elderly Patients With Advanced Prostate Cancer

Phase 2 Not yet recruiting

Prostatic Neoplasms

NCT05059236 2026-04-02

ARASEC

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT07005154 2026-04-02

A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer

Phase 2 Recruiting

Prostatic Neoplasms

NCT07365423 2026-04-02

TerbinaPro

Phase 2 Recruiting

Prostatic Neoplasms

NCT03419234 2026-04-01

Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel

Phase 2 Active not recruiting

223 enrolled 14 charts

Prostatic Neoplasms

NCT04300855 2026-04-01

Clinical Trial of Green Tea Catechins in Men on Active Surveillance

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT04530552 2026-04-01

Testing the Effects of Low Dose Apalutamide on Prostate-Specific Antigen (PSA) Levels in Men Scheduled for Removal of the Prostate Gland

Phase 2 Active not recruiting

34 enrolled 11 charts

Prostatic Neoplasms

NCT05114746 2026-04-01

Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer in Japan

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT06734130 2026-04-01

Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT01251861 2026-03-31

Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer

Phase 2 Active not recruiting

108 enrolled 16 charts

Prostatic Neoplasms

NCT03496805 2026-03-31

Effects of Muscadine Grape Extract in Men With Prostate Cancer on Androgen Deprivation Therapy

Phase 2 Completed

106 enrolled 10 charts

Prostatic Neoplasms

NCT03471650 2026-03-30

Study of PSMA-targeted 18F-DCFPyL PET/CT for the Detection of Clinically Significant Prostate Cancer

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT06244004 2026-03-30

FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer, The PRTY Trial

Phase 2 Recruiting

Prostatic Neoplasms

NCT06395753 2026-03-30

A Dose Finding Study of Debio 4228 in Participants With Advanced Prostate Cancer

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT03436654 2026-03-27

Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT04663997 2026-03-27

177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer

Phase 2 Active not recruiting

Prostatic Neoplasms